Xiangyang Zheng

Xiangyang Zheng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PWPeipei Wang
Peipei Wang
JLJuntao Lin
Juntao Lin
XZXiangyang Zheng
Xiangyang Zheng
XXXingzhi Xu
Xingzhi Xu
Ribonuclease P (RNase P) was first described in the 1970’s as an endoribonuclease acting in the maturation of precursor transfer RNAs (tRNAs). More recent studies, however, have uncovered non-canonical roles for RNase P and its components. Here, we review the recent progress of its involvement in chromatin assembly, DNA damage response, and maintenance of genome stability with implications in tumorigenesis. The possibility of RNase P as a therapeutic target in cancer is also discussed.

8 November 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
GZGuangrong Zhu
Guangrong Zhu
XZXiangyang Zheng
Xiangyang Zheng
ZWZhifeng Wang
Zhifeng Wang
XXXingzhi Xu
Xingzhi Xu
Genomic DNA damage occurs as an inevitable consequence of exposure to harmful exogenous and endogenous agents. Therefore, the effective sensing and repair of DNA damage are essential for maintaining genomic stability and cellular homeostasis. Inappropriate responses to DNA damage can lead to genomic instability and, ultimately, cancer. Protein post-translational modifications (PTMs) are a key regulator of the DNA damage response (DDR), and recent progress in mass spectrometry analysis methods has revealed that a wide range of metabolites can serve as donors for PTMs. In this review, we will summarize how the DDR is regulated by lipid metabolite-associated PTMs, including acetylation, S-succinylation, N-myristoylation, palmitoylation, and crotonylation, and the implications for tumorigenesis. We will also discuss potential novel targets for anti-cancer drug development.